Current developments in the oral drug delivery of fucoidan
Copyright © 2021 Elsevier B.V. All rights reserved..
Fucoidan is well known to have various biological functions and is often investigated for pharmaceutical applications. Several studies have been conducted on clinical applications of fucoidan in recent years, especially regarding its oral drug delivery. Although fucoidan has shown promising results in various dosage forms, its potential applications as a dietary supplement have been demonstrated, and recent studies show that oral administration of fucoidan is preferred. However, the focus on the oral delivery of fucoidan in recent studies has caused its potency in therapy to be understudied. This review aims to provide results on the promising fucoidan activity by oral administration with in vivo studies. In addition to using it as an active ingredient, the utilization of fucoidan as an excipient in oral drug delivery systems will be discussed. An overview of fucoidan administration by oral delivery in recent promising studies will provide a direction for further investigations in clinical applications, particularly for fucoidan, which has a broad spectrum of bioactive properties.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:598 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 598(2021) vom: 01. Apr., Seite 120371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tran, Phuong H L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9072-19-9 |
|---|
| Anmerkungen: |
Date Completed 17.06.2021 Date Revised 17.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2021.120371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321409256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321409256 | ||
| 003 | DE-627 | ||
| 005 | 20231225175739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2021.120371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321409256 | ||
| 035 | |a (NLM)33581274 | ||
| 035 | |a (PII)S0378-5173(21)00175-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tran, Phuong H L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current developments in the oral drug delivery of fucoidan |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2021 | ||
| 500 | |a Date Revised 17.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a Fucoidan is well known to have various biological functions and is often investigated for pharmaceutical applications. Several studies have been conducted on clinical applications of fucoidan in recent years, especially regarding its oral drug delivery. Although fucoidan has shown promising results in various dosage forms, its potential applications as a dietary supplement have been demonstrated, and recent studies show that oral administration of fucoidan is preferred. However, the focus on the oral delivery of fucoidan in recent studies has caused its potency in therapy to be understudied. This review aims to provide results on the promising fucoidan activity by oral administration with in vivo studies. In addition to using it as an active ingredient, the utilization of fucoidan as an excipient in oral drug delivery systems will be discussed. An overview of fucoidan administration by oral delivery in recent promising studies will provide a direction for further investigations in clinical applications, particularly for fucoidan, which has a broad spectrum of bioactive properties | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biological activities | |
| 650 | 4 | |a Dosage form | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Nanocomplex | |
| 650 | 4 | |a Oral fucoidan | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Polysaccharides |2 NLM | |
| 650 | 7 | |a fucoidan |2 NLM | |
| 650 | 7 | |a 9072-19-9 |2 NLM | |
| 700 | 1 | |a Lee, Beom-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Thao T D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 598(2021) vom: 01. Apr., Seite 120371 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:598 |g year:2021 |g day:01 |g month:04 |g pages:120371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2021.120371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 598 |j 2021 |b 01 |c 04 |h 120371 | ||